Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Cervical cancer, predominantly caused by high-risk human papillomavirus (HR-HPV) infections, is a critical public health issue. Effective screening is essential. This study compares the SureX HPV genotyping test, which detects 25 HPV types, with the widely used Digene Hybrid Capture 2 (HC2) test, which targets 13 HR-HPV types, to determine their effectiveness in cervical cancer screening among Chinese women.
Methods: From September to December 2016, women aged 21-64 years in Shanxi Province were screened for cervical cancer using both SureX HPV and HC2 tests. Women with abnormal cytology test would be referred for colposcopy and biopsied if necessary. Concordance rates and kappa coefficients were calculated to analyze the concordance between the two tests. Sensitivity and specificity for detecting cervical intraepithelial neoplasia grade 2 and higher (CIN2+) cases of the two tests were calculated.
Results: Among 3028 subjects analyzed in this study, the positive rate of the common set of 13 HR-HPV types for the SureX HPV test was 15.0%, slightly higher than HC2 test's 13.5%. The overall concordance rate was 93.9% (95% CI: 92.95%-94.66%), with a kappa coefficient of 0.749 (0.715-0.783). Both tests demonstrated a sensitivity of 80.00% (54.81%-92.95%) for detecting CIN2+, with specificities of 85.30% (83.99%-86.52%) for SureX HPV and 86.82% (85.57%-87.98%) for HC2. For CIN3+ detection, both tests had 100% (67.56%-100%) sensitivity, with specificities of 85.20% (83.89%-86.42%) for SureX HPV and 86.72% (85.46%-87.89%) for HC2.
Discussion: The SureX HPV test exhibited excellent concordance with HC2 in detecting the common 13 HR-HPV types and similar sensitivity for identifying CIN2+ cases. Its broader capability to detect 25 HPV genotypes positions it as a promising option for cervical cancer screening.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328181 | PMC |
| http://dx.doi.org/10.3389/fonc.2025.1627935 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the SureX HPV genotyping test with the Digene Hybrid Capture 2 test in cervical cancer screening.
Front Oncol
July 2025
Department of Cancer Epidemiology and Prevention, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
Introduction: Cervical cancer, predominantly caused by high-risk human papillomavirus (HR-HPV) infections, is a critical public health issue. Effective screening is essential. This study compares the SureX HPV genotyping test, which detects 25 HPV types, with the widely used Digene Hybrid Capture 2 (HC2) test, which targets 13 HR-HPV types, to determine their effectiveness in cervical cancer screening among Chinese women.
View Article and Find Full Text PDFClinical performance of the SureX PCR HPV test versus hybrid capture assays (DH2/careHPV) in primary cervical cancer screening.
Tumour Virus Res
June 2025
Gynecological Oncology Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, 830000, China; Xinjiang Key Laboratory of Oncology, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, 830000, China. Electronic address:
Background: Evaluating novel human papillomavirus (HPV) tests in well-designed, population-based screening studies is essential for ensuring the benefits of cervical cancer screening.
Methods: 8638 women aged over 25 years from China underwent HPV screening using a PCR-based full genotyping HPV assay (SureX HPV), alongside hybrid-capture HPV tests (DH2/careHPV) and cytology. Any abnormal results triggered colposcopy and biopsy if indicated.
Ranking the attribution of high-risk genotypes among women with cervical precancers and cancers: a cross-sectional study in Ningbo, China.
Infect Agent Cancer
September 2024
Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 17 South Panjiayuan Lane, P.O. Box 2258, Beijing, 100021, China.
Article Synopsis
- The study investigates the prevalence of high-risk HPV genotypes in Ningbo, China, focusing on their association with cervical intraepithelial neoplasia grade 2 or worse (CIN2+) prior to mass vaccination efforts.
- A total of 1393 biopsy-confirmed CIN2+ cases were analyzed, revealing HPV16 as the most significant genotype, responsible for a large portion of both precancerous lesions and invasive cervical cancers.
- The findings suggest that targeted HPV control efforts should prioritize HPV16 and HPV18, while also considering other genotypes like HPV31, HPV33, HPV45, HPV52, and HPV58 for comprehensive cervical cancer prevention strategies.
Evaluation of an E6/E7 PCR-capillary electrophoresis fragment analysis in the genotyping of human papillomavirus in archival FFPE samples of oropharyngeal cancer.
J Med Virol
June 2024
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Accumulating evidence has demonstrated that high-risk human papillomaviruses (HR-HPVs) are involved in the etiology of a subset of oropharyngeal squamous cell carcinoma (OPSCC). In this regard, the International Agency for Research on Cancer (IARC) has recommended direct molecular HPV testing. So far, there is no agreement on the most appropriate method for HPV detection on OPSCC formalin-fixed paraffin-embedded (FFPE) materials.
View Article and Find Full Text PDFEvaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening.
Virol J
November 2020
Department of Clinical Laboratory, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, 100021, People's Republic of China.
Background: The SureX HPV genotyping test (SureX HPV test), which targets the human papillomavirus (HPV) E6/E7 genes was compared with the Cobas 4800 and Venus HPV tests for detecting 14 high-risk HPV (HR-HPV) types in clinical referral and follow-up patients to evaluate its value for cervical cancer screening.
Methods: Two different populations were enrolled in the study. The first population comprised 185 cases and was used for comparing the SureX HPV test (Health, China) with the Cobas 4800 test (Roche, USA).